To confirm whether miR-22 could directly target sirt1 in breast cancer cells, we constructed luciferase reporter vectors containing the wild type or mutant miR-22 binding sites in the 3′UTR of sirt1 (Fig. 4a). This evidence concerns the gene SIRT1 and breast cancer.